Cytokinetics Inc (NASDAQ: CYTK) open the trading on Wednesday, with a bit cautious approach as it glided -2.07% to $43.63, before settling in for the price of $44.55 at the close. Taking a more long-term approach, CYTK posted a 52-week range of $40.53-$75.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 44.31% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -20.02%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -8.38%. This publicly-traded company’s shares outstanding now amounts to $118.21 million, simultaneously with a float of $115.43 million. The organization now has a market capitalization sitting at $5.17 billion. At the time of writing, stock’s 50-day Moving Average stood at $45.89, while the 200-day Moving Average is $51.60.
Cytokinetics Inc (CYTK) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Cytokinetics Inc’s current insider ownership accounts for 2.52%, in contrast to 109.76% institutional ownership. According to the most recent insider trade that took place on Mar 18 ’25, this organization’s EVP Research & Development sold 2,000 shares at the rate of 43.58, making the entire transaction reach 87,160 in total value, affecting insider ownership by 140,455. Preceding that transaction, on Mar 17 ’25, Company’s EVP, Chief Commercial Officer sold 2,775 for 44.38, making the whole transaction’s value amount to 123,154. This particular insider is now the holder of 34,888 in total.
Cytokinetics Inc (CYTK) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.4 per share during the current fiscal year.
Cytokinetics Inc’s EPS decrease for this current 12-month fiscal period is -8.38% and is forecasted to reach -4.67 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 19.31% through the next 5 years, which can be compared against the -20.02% growth it accomplished over the previous five years trading on the market.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Let’s observe the current performance indicators for Cytokinetics Inc (CYTK). It’s Quick Ratio in the last reported quarter now stands at 6.17. The Stock has managed to achieve an average true range (ATR) of 2.37. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 279.71.
In the same vein, CYTK’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.28, a figure that is expected to reach -1.37 in the next quarter, and analysts are predicting that it will be -4.67 at the market close of one year from today.
Technical Analysis of Cytokinetics Inc (CYTK)
[Cytokinetics Inc, CYTK] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 39.77% While, its Average True Range was 2.35.
Raw Stochastic average of Cytokinetics Inc (CYTK) in the period of the previous 100 days is set at 16.44%, which indicates a major fall in contrast to 24.88% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 38.40% that was lower than 48.84% volatility it exhibited in the past 100-days period.
